An update on the management of glandular fever (infectious mononucleosis) and its sequelae caused by Epstein–Barr virus (HHV-4): new and emerging treatment strategies

References

• Pfeifer E, Drnsenfieber J. Kinderheil/Kd. 1889;29:257–264.
   Google Scholar
• Sprunt TP, Evans FA. Mononuclear leukocytes reaction to acute infection (in infectious mononucleosis). Bull Johns Hopkins Hosp. 1920;31:410–417.
   Google Scholar
• Paul JR, Bunnell WW The presence of heterophile antibodies in infectious mononucleosis. Am J Med Sci. 1932;183:90–103.
   Google Scholar
• Epstein MA, Achong HG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–703.
   PubMed Web of Science ®Google Scholar
• Henle G, Henle W, Diehl V Relation of Burkitt’s tumor associated herpes-type virus to infectious mononucleosis. Proc Natl Assoc Sci U S A. 1968;59:94–101.
   PubMed Web of Science ®Google Scholar
• Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leucocytes. Proc Natl Acad Sci U S A. 1973;70:190–194.
   PubMed Web of Science ®Google Scholar
• Niederman JC, Evans AS. Epstein-Barr Virus. In: Evans AS, Kaslow RA, editors. Viral Infections of Humans: Epidemiology and Control. 4th ed. New York, London: Plenum Medical Book Company; 1997:253–284, Chap 10.
   Google Scholar
• Klemola E, von Essen R, Henle G, Henle W. Infectious mononucleosislike disease with negative heterophile agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis. 1970;121:608–614.
   PubMed Web of Science ®Google Scholar
• Roizman B. The family of herpes viridae: a brief introduction. In: Roizman B, Whitley RJ, Lopez C, editors. The Human Herpes Viruses. New York: Raven Press; 1993:1–10.
   Google Scholar
• Robertson E, editor. Epstein-Barr Virus. Norfolk, England: Caister Academic Press; 2005:770.
   Google Scholar
• Crawford H. Epstein-Barr virus. In: Zuckerman HJ, Banatvala JE, Pattison JR, editors. Principles and Practice of Clinical Virology. 4th ed. John Wiley & Sons Ltd; 2001:117–140.
   Google Scholar
• Hadinoto V Shapiro M, Greenough TC, Sullivan John L, Uzuriaga K, Thorley-Lawson David A. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008;111:1420–1427.
   Web of Science ®Google Scholar
• Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med. 2002;8:594–599.
   PubMed Web of Science ®Google Scholar
• Tsai CH, Williams MV, Glaser R. Characterization of two monoclonal antibodies to Epstein-Barr virus diffuse study antigen which react to two different epitopes and have different biological function. J Virol Methods. 1991;33(1–2):47–52.
   Web of Science ®Google Scholar
• Balfour HH Jr, Holman CJ, Hokanson KM, et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005;192:1505–1512.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Epstein-Barr virus infections, including infectious mononucleosis. In: Kasper DL, Braunwald E, Fauci AS, Longo D, Hauser SL, editors. Harrison ’s Principles oflnternal Medicine. 16th ed. McGraw Hill; 2005:1046–1049.
   Google Scholar
• Henle W, Henle G, Harrison FS, et al. Antibody responses to Epstein-Barr virus and cytomegaloviruses after open-heart and other surgery. N Engl J Med. 1968;282:1068–1074.
   Web of Science ®Google Scholar
• Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010;362:1993–1999.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953–959.
   PubMed Web of Science ®Google Scholar
• Lerner AM, Zervos M, Dworkin HJ, et al. A unified theory of the cause of the chronic fatigue syndrome. Infect Dis Clin Pract. 1997;63:239–243.
   Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, et al. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo. 2004;18:101–106.
   PubMed Web of Science ®Google Scholar
• Tobi M, Morag A, Ravid Z, et al. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet. 1982;1:61–64.
   PubMed Web of Science ®Google Scholar
• Lerner AM, Beqaj S, Fitzgerald JT, et al. Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome. Virus Adapt Treat. 2010;2:1–11.
   Google Scholar
• Tynell E, Aurelius E, Brandell A, et al. Acyclovir and prednisone treatment of acute infectious mononucleosis. A multicenter, double-blind, placebo-controlled study. J Infect Dis. 1996;174:324–331.
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Katano H, Zou P, et al. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected cells, but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol. 2009;83:11857–11861.
   PubMed Web of Science ®Google Scholar
• Henle W, Henle G, Horwitz CA. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Human Pathol. 1974;5:551–565.
   PubMed Web of Science ®Google Scholar
• Horwitz CA, Henle W, Henle G, et al. Long-term serologic follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis. 1985;151:1150–1153.
   Web of Science ®Google Scholar
• Landolfo S, Gariglio G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003;98:269–297.
   PubMed Web of Science ®Google Scholar
• Purifoy DJ, Beauchamp LM, de Miranda P et al. Review of research leading to new anti-herpesvirus agents in clinical development: valacyclovir hydrochloride (256 U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol. 1993;Suppl 1:139–145.
   Google Scholar
• Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valacyclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595–605.
   PubMed Web of Science ®Google Scholar
• Emberg I, Andersson J. Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. J Gen Virol. 1986;67:2267–2272.
   Google Scholar
• Pagano JS, Sixby JW, Lin JC. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother. 1983;12:113–121.
   PubMed Web of Science ®Google Scholar
• Rolan PE, Maillott F, On NT, Posner J. The effects of Cimetidine and probenecid on the conversion of a valacyclovir ester of acyclovir 256U to acyclovir and acyclovir renal clearance in healthy volunteers. Br J Clin Pharmacol. 1993;35:533.
   Google Scholar
• Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharm. 1983;8:187–201.
   Google Scholar
• Laskin OL. Acyclovir pharmacology and clinical experience. Arch Intern Med. 1984;144:1241–1246.
   PubMedGoogle Scholar
• Lycke J, Malmestrom C, Stahle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003;47:2438–2441.
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Faulds D, Goa K, Acyclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:153–205.
   PubMed Web of Science ®Google Scholar
• Pagano JS, Data AK. Perspectives on interactions of acyclovir and Epstein-Barr and other herpesviruses. Am JMed. 1982;73:18–26.
   PubMed Web of Science ®Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs Today. 2002;38(8):549–561.
   Web of Science ®Google Scholar
• Datta AK, Colby BM, Shaw JE, Pagano JS. Acyclovir inhibition of Epstein- Barr virus replication. Proc Natl Acad Sci U S A. 1980;77:5163–5166.
   PubMed Web of Science ®Google Scholar
• Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2- hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol. 1980;34:560–568.
   PubMed Web of Science ®Google Scholar
• Colby BM, Furman PA, Shaw JE, Elion GB, Pagano J. Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl)guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol. 1981;38:606–611.
   Web of Science ®Google Scholar
• St Clair MH, Furman PA, Lubbers CM, et al. Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphates of acyclovir. Antimicrob Agents Chemother. 1980;18:741–745.
   PubMed Web of Science ®Google Scholar
• Furman PA, de Miranda P, St Clair MH, et al. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother. 1981;20:518–524.
   PubMed Web of Science ®Google Scholar
• Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31:543–547.
   PubMed Web of Science ®Google Scholar
• van der Horst C, Joncas J, Ahronheim G, et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis. 1991;164:788–792.
   PubMed Web of Science ®Google Scholar
• Balfour H Jr, Hokanson KH, Schacherer R, et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol. 2007;39(1):16–21.
   PubMed Web of Science ®Google Scholar
• Vere Hodge RA. Review: antiviral portraits series, number 3. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antivir Chem Chemother. 1993;4:67–84.
   Web of Science ®Google Scholar
• Boyd MR, Kern ER, Safrin S. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir Chem Chemother. 1993;4:3–11.
   Web of Science ®Google Scholar
• Hayden FG. Antiviral drugs other than ante-retrovirals. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Disease. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 468–469. Penciclovir and Famciclovir.
   Google Scholar
• Bacon TH, Boyd MR. Activity of penciclovir against Epstein-Barr virus. Antimicrob Agents Chemother. 1995;39(7):1599–1602.
   Web of Science ®Google Scholar
• Straus SE. Epstein-Barr virus and human herpesviruses 6 and 7. In: Gallasso GJ, Whitley RJ, Merigan TC, editors. Antiviral Agents and Human Viral Diseases. Lippincott-Rave Publishers; 708. Chap 18.
   Google Scholar
• Komaroff AL. Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol. 2006;37:S39-S46.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active herpesvirus type 6 infection. Ann Intern Med. 1992;116:103–113.
   PubMed Web of Science ®Google Scholar
• Agut H, Collandre H, Aubin T, et al. In vitro sensitivity of human herpesvirus-6 to antiviral drugs. Res In Virol. 1989;140:219–228.
   PubMedGoogle Scholar
• Lerner Am, Beqaj SH, Fitzgerald JT. Validation of the Energy Index Point Score to serially measure degree of disability in patients with chronic fatigue syndrome. In Vivo. 2008;22:799–802.
   Web of Science ®Google Scholar
• Lerner AM, Zervos M, Dworkin HJ, et al. A new cardiomyopathy: a pilot study of intravenous ganciclovir in a subset of the chronic fatigue syndrome. In Dis In Clin Prac. 1997;16:110–117.
   Google Scholar
• Lerner AM, Dworkin HJ, Sayyed T, et al. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of EBV and/or CMV in patients with chronic fatigue syndrome. In Vivo. 2004;18:417–424.
   Web of Science ®Google Scholar
• Jarisch A. Therapeutische Jersuche bei syphilis. Wien Med Wochenschr. 1895;45:721–742.
   Google Scholar
• Herxheimer K, Krause D. Uber eine bei syphilitischen vorkommende quecksilber-reaktion. Deutch Med Wochenschr. 1902;28:895–897.
   Google Scholar
• Lerner AM, Lawrie-Hoppen C, Dworkin HJ. Repetitively negative changing T-waves at 24-h electrocardiographic monitors in patients with the chronic fatigue syndrome. Left ventricular dysfunction in a cohort. Chest. 1993;104:1417–1420.
   PubMed Web of Science ®Google Scholar
• Rowe PC, Bou-Holaigah I, Kan JS, et al. Is neurally medicated hypotension an unrecognized cause of chronic fatigue syndrome? Lancet. 1995;345:623–624.
   PubMed Web of Science ®Google Scholar
• Dworkin HJ, Lawrie-Hoppen C, Bohdiewiez P, et al. Abnormal left ventricular myocardial dynamics in eleven patients with the chronic fatigue syndrome. Clin Nuc Med. 1994;19:657–677.
   Web of Science ®Google Scholar
• Lerner AM, Goldstein J, Chang CH, et al. Cardiac involvement in patients with the chronic fatigue syndrome as documented with Holter and biopsy data in Birmingham, Michigan. Infect Dis Clin Pract. 1997;6:327–333.
   Web of Science ®Google Scholar
• Webster BH. Cardiac complications of infectious mononucleosis: a review of the literature and report of five cases. Am J Med Sci. 1957;234:62–70.
   Web of Science ®Google Scholar
• Tyson AA Jr, Hackshaw BT, Kutcher MA. Acute Epstein-Barr virus myocarditis simulating myocardial infarction with cardiogenic shock. South Med J. 1989;82:1184–1186.
   Web of Science ®Google Scholar
• Herbert MM, Yu C, Towbin JA, Rogers BB. Fatal Epstein-Barr virus myocarditis in a child with repetitive myocarditis. Fetal Pediatr Pathol. 1995;15:805–812.
   Google Scholar
• LeBlanc MH, Boudriau S, Doyle D, et al. Epstein-Barr virus mediated graft rejection in heart transplant patients: implication of the cardiac cytoskeleton. Transplant Proc. 1998;30:918.
   Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, et al. IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2 (UL44 and UL 57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo. 2002;16:153–160.
   PubMed Web of Science ®Google Scholar
• Beqaj SH, Lerner AM, Fitzgerald JT. Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. J Clin Pathol. 2007;61:623–626.
   Web of Science ®Google Scholar
• Lerner AM, Zervos M, Chang CH, et al. A small randomized placebo controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Clin Infect Dis. 2004;32:1657–1658.
   Google Scholar
• Lerner AM, Beqaj SH, Deeter RJ, et al. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome with long-term thirty-six month follow-up. In Vivo. 2007;21:707–714.
   PubMed Web of Science ®Google Scholar
• Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999;159:2129–2137.
   PubMed Web of Science ®Google Scholar
• Straus SE, Tosato G. Persisting illness and phase complete fatigue in adults with evidence of Epstein-Barr virus infections. Ann Intern Med. 1985;102:7–16.
   PubMed Web of Science ®Google Scholar
• Lombardi VC, Ruscette FW, Das Gupta J, et al. Detection of an infectious retrovirus XMRV in blood cells of patients with chronic fatigue syndrome. Science. 2009;326:585–589.
   PubMed Web of Science ®Google Scholar
• Kumar P, Abhik S, Robertson ES. Epstein-Barr virus hijacks cell-cycle machinery. Microbe. 2010;5:251–256.
   Google Scholar